Steen Klysner

A company providing strategic and operational support for life science executives and managers. S:I:M have successfully supported several companies and foundations within strategy, financing, valuation, business plans, due diligence, and interim management.

Amarna Therapeutics is a privately held biotech company in Leiden in the Netherlands, that develops new gene therapies based on its unique, non-immunogenic vector platform. Major achievements - Obtained financing for the continuation of the company - Developed, re-focused, digitalized, and re-branded the organization - Initiated BD and partnering, making the company a recognized player in the Gene Therapy field

AdaptVac is a joint venture between ExpreS2ion Biotechnologies and NextGen Vaccines from 2017. The company develops new vaccines based on its Virus-Like Particle (VLP) platform. Key achievements - Led the change from semi-academic entity towards a functional business unit - Established partnerships through active engagement in business development & PR - Ensured the consolidation and expansion of crucial proprietary rights

ExpreS2ion Biotech Holding AB is a public Swedish company, listed on Nasdaq First North As CEO, I successfully executed the IPO at Nasdaq First North in Stockholm in 2016, followed by successful emissions in 2017, 2018, and 2019, as well as a convertible bridge loan facility in late 2019. I was managing financing, compliance (Nasdaq, Euroclear, MAR, FI etc.), reporting, IR, press releases as well as the development of an effective branding profile. Key achievements - Sucessfully executed the listing of the company at Nasdaq First North in Stockholm in three months - Execution of three additional successful emissions + a convertible bridge loan facility in three years - Enabled acquisition and development of assets securing growth and multiplying the company's value - Transformed the DK business unit from a CMO to a CDMO / biotech with a valuable pipeline

ExpreS2ion Biotechnologies ApS is a Danish CDMO/Biotech company working with development of vaccines and diagnostics. It is a fully owned subsidiary of the listed ExpreS2ion Biotech Holding AB. As the CEO, I led the management group and spearheaded overall functions of business model, strategy, financing, partnering, and media. Through this, the turnaround and transformation of a staggering CRO business into a CDRO & Biotech company was finalized in three years. This included development of new platform technology and IP, as well as partnerships and new assets providing a high value pipeline and solid growth potential. Key achievements: - Successful execution of a turnround and transformation strategy, taking the company from a CRO to an emerging CDRO/Biotech with valuable pipeline. - Secured future value growth potential and new opportunities through targeted organizational development, partnering and acquisition of new assets.

Member of the company’s executive management team reporting to the CEO. Managing 50 scientists/technicians and all R&D line managers. Responsible for the company’s preclinical R&D, including IP, M&A activities and a recombinant pilot production facility. - Established numerous cutting-edge scientific collaborations and partnerships - Identified and acquired new and innovative platform technology for allergy treatment - Managed the development and transfer of urgent new technology for QC and production

Governance of +100 employees and direct report for the directors of QA and QC. Mediated the development and implementation of new QC analytics and QA alignment to ensure compliance with new guidelines. Responsible for the direct communication with PEI and other authorities on changes, findings, and inspections. Key achievements - Implemented essential adjustments and updates to QA/QC in accordance to new guidelines - Solved urgent, critical technical issues threatening the overall company product pipeline - Successfully managed communication on critical issues with regulatory authorities (PEI/EMEA)

Characterization of isoallergenic variation

Study intermitted by B.Sc in Sports from University of Copenhagen and full time engagement as co-owner of sportschool.